Medullary tumours and Rhabdoid tumours are rare forms of kidney cancer. They are typically treated using very different medications than the ones used for the more common clear cell kidney cancer.
Tazemetostat is an experimental anti-cancer treatment that inhibits a molecule called EZH2. This prevents cancer cells from turning on their genes responsible for growth and division.
This study will investigate the safety and effectiveness of Tazemetostat for treating patients with medullary or rhabdoid kidney cancer. Different doses of Tazemetostat will be used to determine the optimal dosage.
- Medullary or Rhabdoid Kidney Cancer
- Age 6 months – 18 years
- No further standard treatment options available
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre | University Health Network||Principal InvestigatorDr Abha Gupta||LocationToronto, ON||Trial StatusRecruiting|
|Hospital / Cancer CentreAlberta Health Services||Principal Investigator||LocationEdmonton, AB||Trial StatusCompleted|
|Hospital / Cancer CentreMcGill University Health Centre - Royal Victoria Hospital||Principal Investigator||LocationMontreal, QC||Trial StatusCompleted|